• Treace Medical Concepts’ third-quarter 2026 net loss narrowed 23% year over year to $12.6 million.
• Revenue fell to $48.3 million, primarily due to a shift toward lower-priced minimally invasive products and fewer bunion procedure kits sold.
• Operating expenses dropped 10% year over year to $49.9 million, primarily driven by targeted expense reductions.
• Approximately 45% of Lapiplasty surgeon users incorporated at least one of the three bunion systems launched in third-quarter 2025.
• Full-year 2026 revenue guidance narrowed to $206 million–$210 million from $204 million–$212 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060705PRIMZONEFULLFEED9871929) on November 06, 2026, and is solely responsible for the information contained therein.